TIGIT and neoplasm: In addition, SOX9 was mutually exclusive with a variety of tumor immune checkpoints (CD27, CTLA4, LAG3, TIGIT, IL10, CSF1R, ADORA2A, CD244, etc.), further suggesting that SOX9 may be a novel target with great potential in tumor immunotherapy.